Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC118 in Locally Advanced Unresectable/Metastatic Solid Tumours
NCT04914117Phase 1Completed
- Sponsor
- RemeGen
- Start
- Nov 2021
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of RC118 in solid tumor (2 arms), sponsored by RemeGen. Primary endpoints: Maximum Tolerated Dose / Maximum Administered Dose up to 18 months, Recommended Phase 2 Dose up to 18 months and 1 more. Started Nov 2021; status: completed.
02
Drugs
RC118
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04914117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04914117.